Cityblock raised $116M Series E and acquired Homeward Health to expand Medicare Advantage services, as digital health sees ...
Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future ...
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust ...
Pfizer gives Medicus Pharma co-development rights to ADC PF-08046031 for $12M upfront; Novartis consolidating Basel biologics ...
Merck's business development chief Sunil Patel says the drugmaker wants more deals as it diversifies beyond Keytruda ahead of ...
Genentech’s shift from one of the largest drug benefit plans to a privately-held entity is expected to save the Roche subsidiary tens of millions of dollars, the company’s CEO said.
UK regulator halts Tavneos sales; uniQure seeks Huntington's gene therapy approval. Plus Regeneron, Novocure, Jazz, Ascendis, ...
It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent examples). But two cancer ...
Two pediatric deaths in Chinese CRISPR trials reignite debate over AAV delivery risks, as many of the 15 genetic-medicine ...
Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
FDA's Asha Das overruled agency reviewers to grant Replimune's melanoma drug Tudriqev accelerated approval, newly released memos show.
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results